Gain in-depth insights into how ORA™ is revolutionizing endometrial receptivity testing. Download our detailed brochure and sample report and learn more about the benefits for your practice.
ORA™ utilizes a simple blood test, eliminating the need for uncomfortable biopsies.
ORA™ offers clinicians a reliable tool, predicting the optimal implantation window in 95%+ cases.
Our Vault Storage Program simplifies sample storage, ensuring readiness for future analyses.
Clinicians, meet ORA™—the solution to endometrial receptivity testing’s traditional challenges. By analyzing microRNA biomarkers in patients’ blood, ORA™ provides accurate insights into endometrial status, eliminating the need for invasive procedures or mock cycles.
Leveraging microRNA biomarkers, ORA™ offers a revolutionary approach to receptivity testing. These biomarkers reflect endometrial conditions, guiding clinical decisions with precision and confidence.
Compared to traditional tests, ORA™ stands out with its stability and superior pregnancy rates. Clinicians can trust ORA™ for enhanced patient outcomes.
ORA™ significantly boosts pregnancy success rates, exceeding 60% in clinical settings for patients with a history of implantation failure.
ORA™ significantly boosts pregnancy success rates, exceeding 60% in clinical settings for patients with a history of implantation failure.
By replacing biopsies with blood samples, ORA™ enhances patient comfort and compliance.
In cases of inconclusive results, ORA™ allows for additional sampling to refine clinical decisions.
ORA™ empowers clinicians to tailor treatments for optimal outcomes, but it’s not right for every patient. Identify patients who benefit most from ORA™, particularly those with:
Effortless Integration: Incorporate ORA™ seamlessly into treatment protocols, either through our Vault Program or traditional mock cycles.
Clinical Guidance: Navigate sample submission with ease using our straightforward process guidelines.
Empower your patient’s journey with VAULT—a proactive sample storage service designed exclusively for ORA™ users. Here’s how it works:
Access our comprehensive brochure and sample report or connect with us directly for further information and support at [email protected]
For a deeper understanding of the science behind ORA™, read our recently published manuscript in the International Journal of Molecular Sciences:
References
Chen, C. H., Lu, F., Yang, W. J., Yang, P. E., Chen, W. M., Kang, S. T., Huang, Y. S., Kao, Y. C., Feng, C. T., Chang, P. C., Wang, T., Hsieh, C. A., Lin, Y. C., Jen Huang, J. Y., & Wang, L. H. (2021). A novel platform for discovery of differentially expressed microRNAs in patients with repeated implantation failure. Fertility and sterility, 116(1), 181–188.
Chen M-J, Hsu A, Lin P-Y, Chen Y-L, Wu K-W, Chen K-C, Wang T, Yi Y-C, Kung H-F, Chang J-C, et al. Development of a Predictive Model for Optimization of Embryo Transfer Timing Using Blood-Based microRNA Expression Profile. International Journal of Molecular Sciences. 2024; 25(1):76.
